

SWISS HELVETIA FUND, INC.  
Form N-Q  
November 23, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM N-Q**

**QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED**  
**MANAGEMENT INVESTMENT COMPANY**

**Investment Company Act file number: 811-05128**

**THE SWISS HELVETIA FUND, INC.**

(Exact name of registrant as specified in charter)

1270 Avenue of the Americas, Suite 400

New York, NY 10020

(Address of principle executive offices)

**Alexandre de Takacsy, President**

**Banque Hottinger & Cie SA**

**Schutzengasse 30**

**CH-8001 Zurich**

**Switzerland**

(Name and address of agent for service)

**Registrant's telephone number, including area code: 1-888-SWISS-00**

Date of fiscal year end: **December 31**

Date of reporting period: **September 30, 2012**

**Item 1. Schedule of Investments.**

## THE SWISS HELVETIA FUND, INC.

## Schedule of Investments (Unaudited)

September 30, 2012

No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Common Stocks 91.98%</b>			
<b>Banks 3.07%</b>			
91,260	<b>Credit Suisse Group AG</b> <i>Registered Shares</i> A global diversified financial service company with significant activity in private banking, investment banking, asset management and insurance service. (Cost \$2,015,065)	\$ 1,935,318	0.51%
807,000	<b>UBS AG<sup>1</sup></b> <i>Registered Shares</i> A global diversified financial service company with significant activity in private banking, investment banking, and asset management. (Cost \$9,762,573)	9,832,039	2.56%
		11,767,357	3.07%
<b>Biotechnology 4.39%</b>			
179,200	<b>Actelion, Ltd.</b> <i>Registered Shares</i> Focuses on the discovery, development and commercialization of treatments to serve critical, unmet medical needs. (Cost \$7,757,368)	8,977,161	2.34%
301,215	<b>Addex Pharmaceuticals, Ltd.<sup>2</sup></b> <i>Registered Shares</i> Discovers and develops allosteric modulators for human health. Focus is on diseases of the central nervous system. (Cost \$14,144,005)	3,637,785	0.95%
No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Biotechnology (continued)</b>			
3,829,302	<b>Biotie Therapies Oyj<sup>2</sup></b> <i>Bearer Shares</i> Develops drugs that treat dependence disorders, inflammatory diseases, and thrombosis. (Cost \$2,118,548)	\$ 2,019,830	0.53%
3,029	<b>NovImmune SA<sup>2,3</sup></b> <i>Common Shares</i> Discovers and develops therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders. (Cost \$1,551,109)	2,185,212	0.57%
		16,819,988	4.39%
<b>Chemicals 5.98%</b>			
4,400	<b>Givaudan SA</b> <i>Registered Shares</i> Manufactures and markets fragrances and flavors from natural and synthetic ingredients. (Cost \$3,952,933)	4,178,549	1.09%

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

<b>50,115</b>	<b>Syngenta AG<sup>1</sup></b> <i>Registered Shares</i> Produces herbicides, insecticides and fungicides, and seeds for field crops, vegetables, and flowers. (Cost \$15,895,248)	18,743,799	4.89%
		<hr/>	<hr/>
		22,922,348	5.98%

---

*See Notes to Financial Statements.*

## THE SWISS HELVETIA FUND, INC.

Schedule of Investments (Unaudited)  
(continued)

September 30, 2012

No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Common Stocks (continued)</b>			
<b>Construction &amp; Materials 4.08%</b>			
865	<b>Belimo Holding AG</b> <i>Registered Shares</i> World market leader in damper and volume control actuators for ventilation and air-conditioning equipment. (Cost \$577,319)	\$ 1,530,640	0.40%
41,000	<b>Geberit AG</b> <i>Registered Shares</i> Manufactures and supplies water supply pipes and fittings, installation systems, drainage and flushing systems for the commercial and residential construction markets. (Cost \$8,386,321)	8,921,579	2.32%
55,300	<b>Holcim, Ltd.</b> <i>Registered Shares</i> One of the largest cement producers worldwide. (Cost \$3,505,242)	3,524,654	0.92%
825	<b>Sika AG</b> <i>Bearer Shares</i> Leader in processing materials used in sealing, bonding, damping, reinforcing and protecting load-bearing structures with applications for the construction and automotive industry. (Cost \$1,537,859)	1,683,709	0.44%
		15,660,582	4.08%
No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Energy 1.52%</b>			
130,950	<b>Transocean, Ltd.</b> <i>Registered Shares</i> Owns or operates mobile offshore drilling units, inland drilling barges and other assets utilized in the support of offshore drilling activities worldwide. (Cost \$6,789,456)	\$ 5,845,236	1.52%
		5,845,236	1.52%
<b>Financial Services 0.43%</b>			
11,200	<b>Allreal Holding AG</b> <i>Registered Shares</i> Develops and manages real estate. Operates as a general contractor offering planning, architect, and construction management services. (Cost \$1,595,546)	1,644,605	0.43%
		1,644,605	0.43%
<b>Food &amp; Beverages 22.20%</b>			
135	<b>Lindt &amp; Sprungli AG</b> <i>Registered Shares</i>	4,876,835	1.27%

## Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

Major manufacturer of premium Swiss chocolates.  
(Cost \$471,625)

<b>1,271,650</b>	<b>Nestle SA<sup>1</sup></b>		
	<i>Registered Shares</i>	80,239,248	20.93%
	Largest food and beverage processing company in the world. (Cost \$32,035,825)		
		<hr/>	<hr/>
		85,116,083	22.20%

---

*See Notes to Financial Statements.*

## THE SWISS HELVETIA FUND, INC.

Schedule of Investments (Unaudited)  
(continued)

September 30, 2012

No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Common Stocks (continued)</b>			
<b>Industrial Goods &amp; Services 10.94%</b>			
625,700	<b>ABB, Ltd.<sup>1</sup></b> <i>Registered Shares</i> One of the largest electrical engineering firms in the world. Active in industrial automation and in power transmission and distribution. (Cost \$11,992,244)	\$ 11,744,358	3.06%
19,060	<b>Bucher Industries AG</b> <i>Registered Shares</i> Manufactures food processing machinery, vehicles, and hydraulic components. Produces fruit and vegetable juice processing machinery, farming machinery and outdoor equipment. (Cost \$3,794,813)	3,417,334	0.89%
14,730	<b>Burckhardt Compression Holding AG</b> <i>Registered Shares</i> Produces compressors for oil refining and the chemical and petrochemical industries, industrial gases, and gas transport and storage. (Cost \$3,721,139)	4,376,838	1.14%
4,870	<b>Kaba Holding AG</b> <i>Registered Shares</i> Provides mechanical and electronic security systems. Offers individually tailored Total Access Control including high-security locking devices for heavy safes, modular access and time management applications, as well as no-contact identification technology. (Cost \$1,804,119)	1,901,777	0.50%
No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Industrial Goods &amp; Services (continued)</b>			
21,944	<b>Kuehne + Nagel International AG</b> <i>Registered Shares</i> Number one global sea freight forwarder and number two global air cargo forwarder. Also active in contract logistics and rail and road logistics. (Cost \$1,286,640)	\$ 2,479,733	0.65%
3,175	<b>SGS SA</b> <i>Registered Shares</i> Provides industrial inspection, analysis, testing, and verification services worldwide. (Cost \$5,816,646)	6,527,027	1.70%
78,750	<b>Sulzer AG<sup>1</sup></b> <i>Registered Shares</i> Manufactures and sells surface coatings, pumps and process engineering equipment. (Cost \$10,243,337)	11,479,836	3.00%
		41,926,903	10.94%
<b>Insurance 5.50%</b>			
135,942	<b>Swiss Re AG</b> <i>Registered Shares</i>	8,744,088	2.28%



## Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

Offers reinsurance, insurance and insurance-linked financial market products.  
(Cost \$6,981,306)

<b>49,575</b>	<b>Zurich Financial Services AG<sup>1</sup></b>		
	<i>Registered Shares</i>	12,354,187	3.22%
	Offers property, accident, health, automobile, liability, financial risk and life insurance and retirement products. (Cost \$10,728,114)		
		<hr/>	<hr/>
		21,098,275	5.50%

---

*See Notes to Financial Statements.*

## THE SWISS HELVETIA FUND, INC.

## Schedule of Investments (Unaudited)

September 30, 2012

(continued)

No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Common Stocks (continued)</b>			
<b>Medical Technology 1.60%</b>			
168,000	<b>Kuros Biosurgery AG<sup>2,3</sup></b> <i>Common Shares</i> Develops biomaterials and bioactive biomaterial combination products for trauma, wound and spine indications. (Cost \$2,516,639)	\$ 715,046	0.19%
27,300	<b>Sonova Holding AG</b> <i>Registered Shares</i> Designs and produces wireless analog and digital in-the-ear and behind-the-ear hearing aids and miniaturized voice communications systems. (Cost \$2,533,947)	2,761,082	0.72%
3,731	<b>Spineart SA<sup>2,3</sup></b> <i>Common Shares</i> Designs and markets an innovative full range of spine products, including fusion and motion preservation devices, focusing on easy to implant high-end products to simplify the surgical act. (Cost \$2,623,329)	2,659,896	0.69%
		6,136,024	1.60%
<b>Metals &amp; Mining 0.77%</b>			
190,000	<b>Xstrata PLC</b> <i>Common Shares</i> A Diversified mining group, explores for and mines copper, coking coal, thermal coal, ferrochrome, vanadium, zinc, gold, lead and silver. (Cost \$2,811,173)	2,941,583	0.77%
		2,941,583	0.77%
No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Personal &amp; Household Goods 6.24%</b>			
288,050	<b>Compagnie Financiere Richemont SA<sup>1</sup></b> <i>Bearer Shares</i> Manufactures and retails luxury goods. Produces jewelry, watches, leather goods, writing instruments, and men's and women's wear.  (Cost \$15,665,586)	\$ 17,286,678	4.51%
16,650	<b>Swatch Group AG</b> <i>Bearer Shares</i> Manufactures finished watches, movements and components. Produces components necessary to its eighteen watch brand companies. Also operates retail boutiques. (Cost \$5,215,911)	6,647,244	1.73%
		23,933,922	6.24%

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

**Pharmaceuticals 24.42%**

<b>852,300</b>	<b>Novartis AG<sup>1</sup></b> <i>Registered Shares</i>	52,191,812	13.61%
	One of the leading manufacturers of branded and generic pharmaceutical products. Manufactures nutrition products. (Cost \$22,486,214)		
<b>221,600</b>	<b>Roche Holding AG<sup>1</sup></b> <i>Non-voting equity securities</i>	41,429,155	10.81%
	Develops and manufactures pharmaceutical and diagnostic products. Produces prescription drugs in the area of cardiovascular, infectious, autoimmune and respiratory diseases, dermatology, oncology and other areas. (Cost \$20,504,703)		
		<hr/>	<hr/>
		93,620,967	24.42%

See Notes to Financial Statements.

## THE SWISS HELVETIA FUND, INC.

## Schedule of Investments (Unaudited) (continued)

September 30, 2012

No. of Shares	Security	Fair Value	Percent of Net Assets
<b>Common Stocks (continued)</b>			
<b>Retailers 0.84%</b>			
27,020	<b>Dufry AG<sup>2</sup></b> <i>Registered Shares</i> Operates duty-free shops in countries such as Italy, Mexico, France, Russia, the United Arab Emirates, Singapore, the Caribbean and the United States. (Cost \$3,291,650)	\$ 3,240,215	0.84%
		3,240,215	0.84%
	<b>Total Common Stocks</b> (Cost \$246,113,552)	352,674,088	91.98%
<b>Preferred Stocks 2.05%</b>			
<b>Biotechnology 1.18%</b>			
8,400	<b>Ixodes AG, Series B<sup>2,3</sup></b> <i>Preferred Shares</i> Develops and produces a topical product for the treatment of borrelia infection and the prevention of Lyme disease after a tick bite. (Cost \$2,252,142)	2,234,518	0.58%
3,162	<b>NovImmune SA, Series B<sup>2,3</sup></b> <i>Preferred Shares</i> Discovers and develops therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders. (Cost \$2,062,307)	2,281,162	0.60%
		4,515,680	1.18%
<b>Industrial Goods &amp; Services 0.27%</b>			
250,447	<b>SelFrag AG, Class A, Series C<sup>2,3</sup></b> <i>Preferred Shares</i> Designs, manufactures and sells industrial machines and processes using the selective fragmentation technology. (Cost \$1,496,205)	914,060	0.24%
		914,060	0.24%
		1,035,219	0.27%
<b>Industrial Goods &amp; Services (continued)</b>			
33,197	<b>SelFrag AG, Class A, Series D<sup>2,3</sup></b> <i>Preferred Shares</i> Designs, manufactures and sells industrial machines and processes using the selective fragmentation technology. (Cost \$82,670)	\$ 121,159	0.03%
		121,159	0.03%
		1,035,219	0.27%

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

**Medical Technology 0.60%**

<b>83,611</b>	<b>EyeSense AG, Series C<sup>2,3,4</sup> Preferred Shares</b>	2,294,276	0.60%
	A spin-out from Ciba Vision AG. Develops novel ophthalmic self-diagnostic systems for glucose monitoring of diabetes patients. (Cost \$3,007,048)		
		<u>2,294,276</u>	<u>0.60%</u>
	<b>Total Preferred Stocks</b> (Cost \$8,900,372)	7,845,175	2.05%

**Private Equity Limited Partnerships 3.81%**

	<b>Aravis Biotech II - Limited Partnership<sup>2,3,4</sup></b> (Cost \$2,359,547)	1,894,454	0.50%
	<b>Zurmont Madison Private Equity, Limited Partnership<sup>1,2,3,4</sup></b> (Cost \$12,481,353)	12,696,497	3.31%
		<u>14,590,951</u>	<u>3.81%</u>
	<b>Total Private Equity Limited Partnerships</b> (Cost \$14,840,900)	14,590,951	3.81%
	<b>Total Investments*</b> (Cost \$269,854,824)	375,110,214	97.84%
	<b>Other Assets Less Other Liabilities, net</b>	8,296,878	2.16%
	<b>Net Assets</b>	<u>\$ 383,407,092</u>	<u>100.0%</u>

See Notes to Financial Statements.

## THE SWISS HELVETIA FUND, INC.

## Schedule of Investments (Unaudited) (continued)

September 30, 2012

<sup>1</sup> One of the ten largest portfolio holdings.<sup>2</sup> Non-income producing security.<sup>3</sup> Illiquid. There is no public market for these securities. Securities priced at Fair Value as determined by the Board's Pricing Committee. Restricted Securities are not registered under the Securities Act of 1933, as amended. At the end of the period, the aggregate value of these securities amounted to \$27,996,280 or 7.30% of the Fund's net assets. Additional information on these securities is as follows:

Security	Acquisition Date		Acquisition Cost
Aravis Biotech II, LP	July 31, 2007	November 23, 2011	\$ 2,359,547
EyeSense AG Preferred Shares C	July 22, 2010	October 3, 2011	3,007,048
Ixodes AG Preferred Shares B	April 7, 2011	June 1, 2012	2,252,142
Kuros Biosurgery AG Common Shares	August 10, 2009	August 28, 2009	2,516,639
NovImmune SA Common Shares	October 7, 2009	December 11, 2009	1,551,109
NovImmune SA Preferred Shares B	October 7, 2009	December 11, 2009	2,062,307
SelFrag AG Class A, Preferred Shares C	December 15, 2011		1,496,205
SelFrag AG Class A, Preferred Shares D	September 21, 2012		82,670
Spineart SA Common Shares	December 22, 2010		2,623,329
Zurmont Madison Private Equity, LP	September 13, 2007	June 28, 2012	12,481,353
			<u>\$ 30,432,349</u>

<sup>4</sup> Affiliated Company. An affiliated company is a company in which the Fund has ownership of at least 5% of the company's outstanding voting securities. Details related to affiliated company holdings are as follows:

Name of Issuer	Value as of 12/31/11	Gross Additions	Gross Reductions	Income	Value as of 9/30/12
Aravis Biotech II, LP	\$ 2,294,116	\$	\$	\$	\$ 1,894,454
EyeSense AG, Series C	2,305,807				2,294,276
Zurmont Madison Private Equity, LP	9,253,396	2,002,968			12,696,497

\* Cost for Federal income tax purposes is \$269,886,652 and net unrealized appreciation (depreciation) consists of:

Gross Unrealized Appreciation	\$ 121,101,833
Gross Unrealized Depreciation	(15,878,271)
<b>Net Unrealized Appreciation (Depreciation)</b>	<u>\$ 105,223,562</u>

PLC Public Liability Co.

See Notes to Financial Statements.

## THE SWISS HELVETIA FUND, INC.

Schedule of Investments (Unaudited) (concluded)

September 30, 2012

<b>PORTFOLIO HOLDINGS</b>	
<b>% of Net Assets</b>	
Common Stocks	
Pharmaceuticals	24.42%
Food & Beverages	22.20%
Industrial Goods & Services	10.94%
Personal & Household Goods	6.24%
Chemicals	5.98%
Insurance	5.50%
Biotechnology	4.39%
Construction & Materials	4.08%
Banks	3.07%
Medical Technology	1.60%
Energy	1.52%
Retailers	0.84%
Metals & Mining	0.77%
Financial Services	0.43%
Preferred Stocks	
Biotechnology	1.18%
Medical Technology	0.60%
Industrial Goods & Services	0.27%
Private Equity Limited Partnerships	3.81%
Other Assets and Liabilities	2.16%
	100.00%

See Notes to Financial Statements.

---

THE SWISS HELVETIA FUND, INC.

---

Notes to Schedule of Investments (Unaudited)

**Note 1 Organization and Significant Accounting Policies**

**A. Organization**

The Swiss Helvetia Fund, Inc. (the Fund) is registered under the Investment Company Act of 1940, as amended (the Act), as a non-diversified, closed-end management investment company. The Fund is organized as a corporation under the laws of the State of Delaware.

The investment objective of the Fund is to seek long-term growth of capital through investment in equity and equity-linked securities of Swiss companies. The Fund may also acquire and hold equity and equity-linked securities of non-Swiss companies in limited instances.

**B. Securities Valuation**

The Fund values its investments at fair value in accordance with accounting principles generally accepted in the United States (GAAP).

When valuing listed equity securities, the Fund uses the last sale price prior to the calculation of the Fund's net asset value (NAV). When valuing equity securities that are not listed (except privately-held companies and private equity limited partnerships) or that are listed but have not traded, the Fund uses the mean between the bid and asked prices for that day.

When valuing fixed-income securities, the Fund uses the last bid price prior to the calculation of the Fund's NAV. If a current bid price is not available, the Fund uses the mean between the last quoted bid and asked prices. When valuing fixed-income securities that mature within sixty days of acquisition, the Fund uses amortized cost, which approximates fair value.

It is the responsibility of the Fund's Board of Directors (the Board) to establish fair valuation procedures. When valuing securities for which market quotations are not readily available, or for which the market quotations that are available are considered unreliable, the Fund determines a fair value in good faith in accordance with these procedures (a Fair Value). The Fund may use these procedures to establish the Fair Value of securities when, for example, a significant event occurs between the time the market closes and the time the Fund values its investments. After consideration of various factors, the Fund may value the securities at their last reported price or at some other value. Additional consideration is given to securities that have experienced a decrease in the volume or level of activity or to circumstances that indicate that a transaction is not orderly.

Swiss exchange-listed options or options that are not listed at the request of a counterparty are valued using implied volatilities as input into widely accepted models (e.g., Black-Scholes). Eurex-listed options are valued at their most recent sale price (latest bid for long options and the latest ask for short options), or if there are no such sales, at the average of the most recent bid and asked quotations, or if such quotations are not available, at the last bid quotation in the case of purchased options or the last asked quotation in the case of written options; however, if there are no such quotations, such contracts will be valued using the implied volatilities observed for similar options as an input to a model. Options



## Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

traded in the over-the-counter market are valued at the price communicated by the counterparty to the option, which typically is the price at which the counterparty would close out the transaction.

The Fund is permitted to invest in investments that do not have readily available market quotations. For such investments, the Act requires the Board to determine their Fair Value. The Fund's investments of this type have been Fair Valued at \$27,996,280, or 7.30% of the Fund's net assets at September 30, 2012, and are listed in Note 3 to the Schedule of Investments. These investments also are considered Level 3 investments under GAAP as described below.

Various inputs are used to determine the value of the Fund's investments. These inputs are summarized in the three broad levels listed below:

Level 1 unadjusted quoted prices in active markets for identical assets and liabilities

## THE SWISS HELVETIA FUND, INC.

## Notes to Schedule of Investments (Unaudited) (continued)

Level 2 other significant observable inputs (including quoted prices of similar securities, interest rates, prepayment speeds, credit risk, etc.)

Level 3 significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments)

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund's net assets as of September 30, 2012:

	Level 1 Quoted Prices	Level 2 Other Significant Observable Inputs	Level 3 Significant Unobservable Inputs	Total
<b>Investments in Securities</b>				
Common Stock*	\$ 347,113,934	\$	\$ 5,560,154	\$ 352,674,088
Preferred Stock*			7,845,175	7,845,175
Private Equity Limited Partnerships			14,590,951	14,590,951
<b>Total Investments in Securities</b>	<b>\$ 347,113,934</b>	<b>\$</b>	<b>\$ 27,996,280</b>	<b>\$ 375,110,214</b>

\* Please see the Schedule of Investments for industry classifications.

The inputs and valuation techniques used to value the exchange-listed corporate convertible bond, classified as a Level 2 security, are based on a pricing service model, which may include consideration of dealer quotes, trade execution data, conversion prices compared to the current market quotation of the underlying stock and, when available, the last sale price on the exchange on which it trades.

Level 3 securities, which are listed in Note 3 to the Schedule of Investments, consist of the Fund's investments in privately-held companies and private equity limited partnerships that invest in privately-held companies.

Inputs and valuation techniques used by the Fund to value its Level 3 investments in privately-held companies may include the following: acquisition cost; fundamental analytical data; discounted cash flow analysis; nature and duration of restrictions on disposition of the investment; public trading of similar securities of similar issuers; economic outlook and condition of the industry in which the issuer participates; financial condition of the issuer; and the issuer's prospects, including any recent or potential management or capital structure changes. At September 30, 2012, privately-held companies, except Eyesense AG, Kuros Biosurgery AG and SelFrag AG, were valued based on a market approach using the most recent observable round of financing, which may also have been acquisition cost. Although these valuation inputs may be observable in the marketplace as is characteristic of Level 2 instruments, the privately-held companies, categorized as Level 3 investments, generally are highly illiquid in terms of resale.

## Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

The Fund values its Level 3 investments in the two private equity limited partnerships in accordance with Accounting Standards Codification 820-10-35, *Investments in Certain Entities that Calculate Net Asset Value Per Share (Or its Equivalent)* (ASC 820-10-35). ASC 820-10-35 permits a reporting entity to measure the fair value of an investment that does not have a readily determinable fair value, based on the NAV of the investment as a practical expedient, without further adjustment, unless it is probable that the investment will be sold at a value significantly different than the NAV. If the NAV of the investment is not as of the Fund's measurement date, then the NAV should be adjusted to reflect any significant events that may change the valuation. Inputs and valuation techniques for these adjustments may include fair valuations of the partnerships and their portfolio holdings provided by the partnerships' general partners or managers, other available information about the partnerships' portfolio holdings, values obtained on redemption from other limited partners, discussions with the partnerships' general partners or managers and/or other limited partners and comparisons of previously-obtained estimates to the partnerships' audited financial statements. In using the NAV as a practical expedient, certain attributes of the investment that may impact its fair value are not considered. Attributes of

## THE SWISS HELVETIA FUND, INC.

## Notes to Schedule of Investments (Unaudited) (continued)

those investments include the investment strategies of the privately-held companies and may also include, but are not limited to, restrictions on the investor's ability to redeem its investments at the measurement date and any unfunded commitments.

When valuing Level 3 investments, management also may consider potential events that could have a material impact on the operations of a privately-held company or private equity limited partnership. Not all of these factors may be considered or available, and other relevant factors may be considered on an investment-by-investment basis. The table below summarizes the techniques and unobservable inputs for the valuation of the Level 3 investments.

Quantitative Information about Level 3 Fair Value Measurements

Type of assets	Fair Value		Valuation technique	Unobservable inputs	Range*
	at 9/30/2012				
Equity venture direct investment Medical Technology**	\$3,009,322		Discounted Cash Flow	Weighted average cost of capital Success rate on research and development Expected long-term 10-year revenue growth rate	12%-18% 60%-90% 15%-25%
Equity venture direct investment Industrial Goods & Services***	\$1,035,219		Discounted Cash Flow	Weighted average cost of capital Success rate on research and development Expected long-term 10-15 year revenue growth rate	18%-25% 20%-70% 10%-15%

\* Significant changes in any of these ranges would result in a significantly higher or lower fair value measurement. Generally, a change in the success rate on research and development or the expected long-term 10-year revenue growth rate is accompanied by a directionally similar change in fair value. Conversely, a change in the weighted average cost of capital is accompanied by a directionally opposite change in fair value.

\*\* Eyesense AG Preferred Shares and Kuros Biosurgery AG Common Shares were valued based on this technique.

\*\*\* SelFrag AG Preferred Shares were valued based on this technique. (The inputs range corresponds to different stages of the company's development.)

The Fund's policy is to disclose transfers between Levels based on market prices at the reporting period end. For the nine-month period ended September 30, 2012, shares of Biotie Therapies OYJ ( Biotie ), which are publicly traded on the NASDAQ OMX Helsinki Stock Exchange, were transferred from Level 2 to Level 1. The Fund applied a liquidity discount to market quotations for shares of Biotie during a contractual lock-up period that expired on February 2, 2012. Beginning February 2, 2012, Biotie was valued solely based on market quotations.

## THE SWISS HELVETIA FUND, INC.

## Notes to Schedule of Investments (Unaudited) (continued)

The following is a reconciliation of Level 3 assets for which significant unobservable inputs were used to determine fair value.

	Common Stock	Preferred Stock	Private Equity	Total
Balance as of December 31, 2011	\$ 7,779,951	\$ 7,699,706	\$ 11,547,512	\$ 27,027,169
Change in Unrealized Appreciation/Depreciation	(2,219,797)	(554,644)	1,040,471	(1,733,970)
Net Realized Gain (Loss)				
Gross Purchases		700,113	2,002,968	2,703,081
Gross Sales				
Balance as of September 30, 2012	\$ 5,560,154	\$ 7,845,175	\$ 14,590,951	\$ 27,996,280

## C. When-Issued and Delayed-Delivery Transactions

The Fund may purchase or sell securities on a when-issued or delayed-delivery basis. The Fund records when-issued or delayed-delivery securities as of trade date and maintains security positions such that sufficient liquid assets will be available to make payment for the securities purchased. Securities purchased on a when-issued or delayed-delivery basis are marked-to-market daily and, in the case of fixed-income securities, begin earning interest on the settlement date. The Fund may dispose of or renegotiate a delayed-delivery transaction after it is entered into, which may result in a capital gain or loss. Losses may occur on these transactions due to changes in market conditions or the failure of counterparties to perform under the contract.

## D. Options

The Fund may buy call options and put options, and may sell (write) covered call options. Options may be entered into on securities in which the Fund may invest and on Swiss stock indices. Option contracts are utilized to manage the Fund's exposure to changing security prices and, in the case of written options, to generate income. Purchasing call options tends to increase the Fund's exposure to the underlying instrument. Purchasing put options tends to decrease the Fund's exposure to the underlying instrument. The Fund pays a premium as an investment that is subsequently marked-to-market to reflect the current value of the option purchased. Premiums paid for purchasing options which expire are treated as realized losses. The risk associated with purchasing put and call options is limited to the premium paid and the exposure to the risk that the counterparty would be unable to meet the terms of the contract. Premiums paid for purchasing options which are exercised or closed are added to the amounts paid or offset against the proceeds on the underlying instrument to determine the realized gain or loss.

Writing call options tends to decrease the Fund's exposure to the underlying instrument. When the Fund writes a call option, such option is covered, meaning that the Fund holds the underlying instrument subject to being called by the option counterparty. When the Fund writes a call option, an amount equal to the premium received is recorded as a liability and subsequently marked-to-market to reflect the current value of the option written. Premiums received from writing options which expire are treated as realized gains. Premiums received from writing options which are exercised or closed are added to the proceeds or offset against amounts paid on the underlying instrument to determine the realized gain or loss. The Fund as a writer of an option has no control over whether the option will be exercised and, as a result, bears the market risk of an unfavorable change in the price of the instrument underlying the written option. There is the risk the Fund may not be able to enter into a closing transaction because of an illiquid market.

The Fund did not enter into any option transactions during the nine-month period ended September 30, 2012, and the Fund held no contracts at September 30, 2012.

**E. Foreign Currency Translation**

The Fund maintains its accounting records in U.S. dollars. The Fund's assets are invested primarily in Swiss equities and equity-linked securities. In addition, the Fund makes its temporary investments in Swiss franc-denominated bank deposits, short-term debt

---

 THE SWISS HELVETIA FUND, INC.
 

---

**Notes to Schedule of Investments (Unaudited) (concluded)**

securities and money market instruments. Substantially all income received by the Fund is in Swiss francs. The Fund's NAV, however, is reported, and distributions from the Fund are made, in U.S. dollars, resulting in gain or loss from currency conversions in the ordinary course of business. Historically, the Fund has not entered into transactions designed to reduce currency risk and does not intend to do so in the future. The cost basis of foreign denominated assets and liabilities is determined on the date that they are first recorded within the Fund and translated to U.S. dollars. These assets and liabilities are subsequently valued each day at prevailing exchange rates. The difference between the original cost and current value denominated in U.S. dollars is recorded as unrealized foreign currency gain/loss. In valuing securities transactions, the receipt of income and the payment of expenses, the Fund uses the prevailing exchange rate on the transaction date.

**F. Estimates**

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Schedule of Investments. Actual results could differ from those estimates.

**G. Concentration of Market Risk**

The Fund primarily invests in securities of Swiss issuers. Such investments may carry certain risks not ordinarily associated with investments in securities of U.S. issuers. These risks include future political and economic developments, unfavorable movements in the U.S. dollar relative to the Swiss franc, and the possible imposition of exchange controls and changes in governmental law and restrictions. In addition, concentrations of investments in securities of issuers located in a specific region exposes the Fund to the economic and government policies of that region and may increase risk compared to a fund whose investments are more diversified.

**Note 2 Capital Commitments**

As of September 30, 2012, the Fund maintains certain illiquid investments in two limited partnerships and one corporation. The Fund's investments are summarized in the Schedule of Investments. The Fund's capital commitments and the amounts disbursed to these issuers are shown in the table below:

Investments	Original Capital Commitment*	Unfunded Commitment*	Fair Value as of September 30, 2012
<b>Limited Partnerships International (a)</b>			
Aravis Biotech II, LP	\$ 3,458,183	\$ 831,347	\$ 1,894,454
Zurmont Madison Private Equity, LP	14,896,787	1,560,632	12,696,497
<b>Preferred Stock International</b>			
SelFrag AG, Class A, Series D (b)	82,040	82,040	121,159

\* The original capital commitment represents 3,250,000, 14,000,000 and 77,101 Swiss francs for Aravis Biotech II, LP, Zurmont Madison Private Equity, LP and SelFrag AG, respectively. The unfunded commitment represents 781,300, 1,466,682 and 77,101 Swiss francs, respectively. The Swiss franc (CHF)/U.S. dollar exchange rate as of September 30, 2012 was used for conversion and equals 0.9398.

## Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

*(a) This category consists of two private equity limited partnerships that invest primarily in ventures, biotechnology and in management buyout of industrial and consumer goods companies. There is no redemption right for the interests in these two limited partnerships. Instead, the nature of the investments in this category is that distributions are received through the realization of the underlying assets of the limited partnership. If these investments were held, it is estimated that the underlying assets of each limited partnership would be realized over 3 to 4 years.*

*(b) The unfunded commitment for this security represents a capital commitment in a future round of financing, which has been approved by shareholders but is contingent upon action by the board of directors of SelFrag AG, on or before December 31, 2013.*

THE SCHEDULE OF INVESTMENTS SHOULD BE READ IN CONJUNCTION WITH THE FINANCIAL STATEMENTS AND NOTES TO FINANCIAL STATEMENTS WHICH ARE INCLUDED IN THE FUND'S SEMIANNUAL REPORT OR AUDITED ANNUAL REPORT. THESE REPORTS INCLUDE ADDITIONAL INFORMATION ABOUT CERTAIN SECURITY TYPES INVESTED IN BY THE FUND.



**Item 2. Controls and Procedures.**

- (a) The registrant's principal executive officer and principal financial officer have concluded, based on their evaluation of the registrant's disclosure controls and procedures as conducted within 90 days of the filing date of this report, that these disclosure controls and procedures are adequately designed and are operating effectively to ensure that information required to be disclosed by the registrant on Form N-Q is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms.
  
- (b) There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the Act (17 CFR 270.30a-3(d)) that occurred during the registrant's most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the registrant's internal control over financial reporting.

**Item 3. Exhibits.**

Certifications pursuant to Rule 30a-2(a) are attached hereto.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant):                   The Swiss Helvetia Fund, Inc.

By (Signature and Title)\*:   /s/ Rudolf Millisits  
Rudolf Millisits, Chief Executive Officer

Date: November 20, 2012

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By (Signature and Title)\*:   /s/ Rudolf Millisits  
Rudolf Millisits, Chief Executive Officer

Date: November 20, 2012

By (Signature and Title)\*:   /s/ Philippe R. Comby  
Philippe R. Comby, Chief Financial Officer

Date: November 20, 2012